DARE
NASDAQDare Bioscience Inc.
Price$1.95+0.03 (+1.57%)
01:30 PM07:45 PM
News · 26 weeks58+18%
2026-01-182026-07-12
Mix3690d
- SEC Filings15(42%)
- Insider10(28%)
- Other9(25%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 253G2 filed by Dare Bioscience Inc.253G2 - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell EventLive video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET. For the segment, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, will provide a brief corporate overview highlighting the recent launch of FloraSync LF5™, the Company's strategy for thoughtfully building its commercial business while adv
- INSIDERDirector Matz Gregory W was granted 30,805 shares, increasing direct ownership by 73,345% to 30,847 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Kelley Susan L. was granted 23,696 shares (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Grossman Jessica D. was granted 26,066 shares (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Rastetter William H was granted 38,862 shares, increasing direct ownership by 4,524% to 39,721 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Steele Robin Joan was granted 26,540 shares, increasing direct ownership by 129% to 47,055 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- PRDaré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer PlatformSAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort, is now available for order. Flora Sync LF5 sales will mark the Company’s first direct consumer product revenue, representing Daré Bioscience’s transition from a pure development-stage biotech to a women’s health company with a revenue-generating product. Flora Sync LF5 is available exclusively through the DARE Hea
- PRDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” SegmentFirst consumer health product positions Daré for revenue generation while expanding its women's health leadership platform Access the segment here SAN DIEGO, June 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the company’s recent news announcing the upcoming June 2026 commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. For the
- SECSEC Form S-8 filed by Dare Bioscience Inc.S-8 - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that President and Chief Executive Officer, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a Company corporate presentation during the BIO International Convention 2026, taking place June 22-25 in San Diego, California. As one of the biotechnology industry's premier global gatherings, BIO International Convention brings together thousands of executives, investors, innovators, policymakers and strategic partners
- SECDare Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- INSIDERSEC Form 4 filed by Director Rastetter William H4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERSEC Form 4 filed by Director Grossman Jessica D.4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERSEC Form 4 filed by Director Matz Gregory W4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERSEC Form 4 filed by Director Steele Robin Joan4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelley Susan L.4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- PRDaré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic CapsulesFirst Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June
- SECSEC Form DEFA14A filed by Dare Bioscience Inc.DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form DEFA14A filed by Dare Bioscience Inc.DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerReceipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatmentsAward reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contra
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Dare Bioscience, Inc. (0001401914) (Filer)
DARE FAQ
7 questionsWhat does Dare Bioscience Inc. do?
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil...Where does DARE stock trade?
Dare Bioscience Inc. (DARE) is listed on NASDAQ.What sector and industry is DARE in?
Dare Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dare Bioscience Inc. go public?
Dare Bioscience Inc. (DARE) completed its IPO in 2014.What are analysts saying about DARE?
Dare Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1100.00 price target on 2021-06-30. Recent price targets cluster around $1100.00.What companies are similar to DARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DARE side-by-side with any of them on Quantisnow.How can I track DARE on Quantisnow?
Quantisnow aggregates Dare Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DARE to receive live email and push alerts on every new disclosure.